For this in-depth comparison, the useful starting point is not whether the internet is excited about it. It is whether the evidence, safety limits, prescription pathway, and follow-up plan are strong enough to support a real patient decision.
A friend of mine, a nurse practitioner in Tampa, told me about a patient who showed up to her intake appointment last fall with a three-ring binder. Printed Reddit threads. Screenshots of TikTok comments. A spreadsheet comparing five different telehealth semaglutide programs by price, pharmacy source, and shipping time. The woman had done more competitive analysis than most venture capitalists do before a seed round. What she hadn’t done was ask whether her levothyroxine dose might need monitoring once she started a GLP-1 agonist.
That story captures something real about where the compounded semaglutide conversation sits right now. Most adults landing on pages like this one aren’t asking “what is semaglutide?” They’re past that. They want to know: what dose, what side effects to actually expect, what it costs, and whether the compounded version is meaningfully different from what Novo Nordisk sells for $1,300 a month. Fair questions. This is the briefing I’d want to read if I were that person.
The Drug Itself (and Why “Compounded” Isn’t a Dirty Word)
Semaglutide is a GLP-1 receptor agonist, originally developed by Novo Nordisk and brought to market as Ozempic in 2017 for type 2 diabetes, then as Wegovy in 2021 for chronic weight management. The molecule mimics an incretin hormone your gut already makes in response to food. It stimulates insulin secretion in a glucose-dependent way (meaning it’s not pushing insulin when your blood sugar is already low), suppresses glucagon after meals, slows gastric emptying, and acts on hypothalamic circuits that regulate appetite. The combination of these effects is what produces both the glycemic improvement and the weight loss.
Compounded semaglutide uses the same active pharmaceutical ingredient. The difference is the supply pathway: it’s prepared by a state-licensed or 503A compounding pharmacy for an individual patient under a clinician’s prescription, rather than arriving as a finished product off Novo Nordisk’s manufacturing line. This falls under section 503A of the Federal Food, Drug, and Cosmetic Act and parallel state pharmacy regulations. It’s not some gray-market workaround. Compounding has been part of US pharmacy practice across dozens of drug classes for decades.
The critical distinction: compounded semaglutide is not FDA-approved as a finished product. The clinical trial data (STEP, SUSTAIN) was generated with the branded formulations. The pharmacological effect of the active ingredient is expected to track, but compounded preparations haven’t been studied as finished products in registrational trials. That’s a real difference, and it’s one worth naming honestly rather than waving away.
What the Trial Data Actually Shows
The headline trial is STEP-1, which randomized 1,961 adults with overweight or obesity (without diabetes) to weekly semaglutide 2.4 mg or placebo for 68 weeks alongside lifestyle intervention. The semaglutide group lost approximately 14.9% of body weight from baseline, compared with 2.4% for placebo (Wilding et al., New England Journal of Medicine, 2021). Individual responses ranged widely, which is the part that gets lost in the headline number. Some patients lost 5%. Some lost 25%.
STEP-3 layered intensive behavioral therapy on top and showed a somewhat larger effect in the same direction. STEP-5 extended follow-up to 104 weeks and reported sustained weight reduction in the active arm. STEP-4 is the one that keeps clinicians honest: patients who were switched to placebo after an initial treatment period showed significant regain, indicating the metabolic effect depends on continued therapy for many people. Weight loss on semaglutide is not like a course of antibiotics. It’s more like blood pressure medication: the effect persists while you’re taking it.
On the diabetes side, the SUSTAIN program established the glycemic benefit at the lower dose range (0.5 mg and 1.0 mg weekly, with 2.0 mg added later in SUSTAIN FORTE). SUSTAIN-6, the cardiovascular outcome trial, reported a reduction in the composite of major adverse cardiovascular events in a high-risk diabetes population (Marso SP et al.).
The Titration Schedule, and Why Patience With It Matters
The standard escalation from the STEP trials and the Wegovy label runs five steps: 0.25 mg weekly for four weeks, then 0.5 mg for four weeks, 1.0 mg for four weeks, 1.7 mg for four weeks, and finally 2.4 mg as the maintenance dose. Full escalation takes about sixteen weeks if you hold each step for four weeks.
Most compounded programs follow this same schedule and the same milligram increments. Here’s the operational catch: because compounding pharmacies vary in the concentration of their preparations, the volume you draw into the syringe might be different from what someone on Reddit says they’re injecting. The dose in milligrams is what matters clinically. Not the volume of solution. If you’re switching programs or pharmacies, confirm your milligram dose at each step.
The schedule is not a rigid escalator. A patient struggling with nausea at 0.5 mg can sit at that dose for an extra four weeks (or longer) before moving up. A patient who’s responding well at 1.7 mg can stay there if the clinical picture supports it. Pushing to 2.4 mg isn’t mandatory. That’s a clinical decision, made between a patient and their prescriber, not a checkbox.
Injection-site rotation between abdomen, thigh, and upper arm reduces local irritation. Refrigerate at 36 to 46°F, with limited room-temperature excursions acceptable for transport. Pick the same day each week. These are small details, but they’re the details that determine whether the day-to-day experience is tolerable or annoying.
Side Effects: the First Eight Weeks Are the Worst
Gastrointestinal symptoms dominate. Nausea, diarrhea, constipation, vomiting, abdominal discomfort. Across STEP and SUSTAIN and in real-world cohorts, the pattern is consistent: most events are mild to moderate, concentrated in the first eight to twelve weeks, and resolve with continued therapy or temporary dose adjustment. This is the period where patients are most likely to quit, and it’s the period where a program’s clinical support structure matters most.
Less common but clinically important: gallbladder events (especially in patients losing weight rapidly), acute pancreatitis (rare but requires immediate evaluation if severe abdominal pain radiates to the back), and a theoretical thyroid C-cell tumor signal from rodent data that has not been replicated in humans. Both Wegovy and Ozempic carry a boxed warning on the thyroid finding and a contraindication in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2).
Hypoglycemia is uncommon on semaglutide alone in non-diabetic patients because the insulin effect is glucose-dependent. The risk goes up when semaglutide is combined with insulin or sulfonylureas, and the fix is adjusting the dose of those other agents, not necessarily stopping semaglutide.
One thing that doesn’t get enough attention: semaglutide slows gastric emptying, which can affect absorption of other oral medications. Patients on warfarin or other drugs with narrow therapeutic windows should flag this with their prescriber. My Tampa NP friend’s patient with the binder? She was on levothyroxine, which is notoriously finicky about absorption timing. That’s the kind of thing a good intake conversation catches.
See also: What Are Utility Tokens in Crypto?
The Money Part
Brand-name Wegovy and Ozempic carry list prices north of $1,300 per month. Cash-pay rates at most retail pharmacies land in the $1,000 to $1,400 range. Insurance coverage for weight-management indications is inconsistent (a polite way of saying many plans don’t cover it). The diabetes indication has better coverage but still varies by plan.
Compounded semaglutide programs in compliant telehealth structures price substantially lower. HealthRX, for example, runs $179.99 to $279.99 per month depending on dose, available in 44 US states and operated under LegitScript certification.
The pricing gap is structural, not suspicious. Brand-name products carry the cost of manufacturing scale-up, regulatory submissions, post-marketing surveillance, commercial distribution, and the margin that funds Novo Nordisk’s next generation of research. Compounded preparations are produced at a different scale through a different regulatory pathway with a fundamentally different cost structure. Both pathways are legal. They serve different segments of the market.
If you’re using an HSA or FSA, confirm the program’s invoicing format before enrollment. Some plans reimburse compounded medications without issue. Some don’t. Better to find out before you submit a receipt.
Compounded vs. Brand-Name: Honest Framing
This is best understood as a comparison of supply pathways for the same active ingredient, not as a quality hierarchy. The brand-name products have registrational trial data behind them, an FDA-approved label, and Novo Nordisk’s industrial manufacturing infrastructure. Compounded preparations use the same active molecule, are prepared by licensed compounding pharmacies for individual patients, and are not FDA-approved as finished products.
Three practical implications follow from that. First, the STEP and SUSTAIN evidence base was built on the brand-name formulation and informs but does not directly extend to compounded preparations. Second, manufacturing oversight differs: compounding pharmacies are regulated by state boards of pharmacy (and by FDA under a separate framework for 503B outsourcing facilities), not under the same system as finished-product manufacturers. Third, adverse-event surveillance is less systematic for compounded preparations.
None of that means compounded semaglutide is inferior by default. It means the evaluation framework is different, and a responsible patient reference should name those differences rather than flatten them into a marketing pitch. Patients who want a fuller side-by-side breakdown can read this in-depth comparison, which walks through the clinical and practical questions that typically come up in an actual intake conversation. It’s not a substitute for talking to a clinician. It’s the kind of reading that makes that conversation more efficient.
When to Call Your Prescriber (Not Google)
Some scenarios warrant a phone call, not a search engine:
Persistent severe abdominal pain, especially with radiation to the back or fever. Inability to keep down fluids for more than 24 hours, signs of dehydration, or persistent vomiting. New gallbladder symptoms (right upper quadrant pain after meals, jaundice). Reflux that doesn’t respond to meal-timing adjustments. Mood changes, including new or worsening depressive symptoms.
Pregnancy, planned pregnancy, or breastfeeding: have the conversation before your next dose. Personal or family history of medullary thyroid carcinoma or MEN2 is a contraindication that should have been caught at intake. If it wasn’t, raise it now.
Patients on insulin, sulfonylureas, or other glucose-lowering agents who notice hypoglycemic episodes need dose adjustment of the concurrent therapy. Don’t just white-knuckle through low blood sugar readings.
Frequently Asked Questions
Is compounded semaglutide the same drug as Ozempic and Wegovy? The active ingredient, semaglutide, is the same. The finished product, the regulatory category, and the manufacturing pathway are different. Brand-name Ozempic and Wegovy are FDA-approved finished products manufactured by Novo Nordisk. Compounded semaglutide is prepared by a licensed compounding pharmacy for an individual patient under a clinician’s prescription and is not FDA-approved as a finished product.
How long does treatment typically last? STEP-1 captures 68 weeks; STEP-5 extends to 104 weeks; clinical experience now stretches beyond two years. Duration is individualized based on goals, response, and tolerability.
Is the weight loss sustained after stopping? STEP-4 showed significant regain in the group switched to placebo after a lead-in period. For many patients, maintaining the effect requires continued therapy. Long-term outcomes after discontinuation depend heavily on lifestyle changes consolidated during treatment.
Do I need labs to start? A responsible program will order baseline labs, typically including a metabolic panel, lipid panel, A1c, and sometimes a thyroid panel. The specific set depends on your clinical picture.
Is semaglutide appropriate for everyone? No. Pregnancy, breastfeeding, personal or family history of medullary thyroid carcinoma or MEN2, and certain GI conditions are contraindications or relative contraindications. A thorough intake conversation should surface these before therapy begins.
Can I switch between compounded and brand-name semaglutide? In principle, yes, since the active ingredient is the same. Confirm the milligram dose with your prescriber when transitioning to avoid dosing errors due to different concentrations.
What happens if I miss a dose? If fewer than five days have passed since your scheduled dose, take it as soon as you remember. If five or more days have passed, skip the missed dose and resume on your next scheduled day. Don’t double up.
References: Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 2021;384:989-1002 (STEP-1). Wadden TA et al. STEP-3. Rubino DM et al. STEP-4. Garvey WT et al. STEP-5. Davies M et al. STEP-2. SUSTAIN-6 (Marso SP et al.). Wegovy and Ozempic prescribing information (Novo Nordisk).
Important Notice
Not FDA-approved. Compounded semaglutide is prepared by licensed compounding pharmacies for individual patients based on a prescriber’s clinical judgment. This article is educational and does not constitute medical advice. Individual results vary.
